Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

about

Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

Item

http://www.wikidata.org/entity/Q38848793

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

@en

type

Item

label

Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

@en

prefLabel

Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

@en

P1476

Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

@en

P2093

Leonard B Saltz

http://www.w3.org/2001/XMLSchema#string

P2860

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl

First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.

Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.

Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.

Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis.

P304

232-235

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PPO.0000000000000194

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27341604

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5543411

http://www.w3.org/2001/XMLSchema#string

Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

about

Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932